NRG3 Human Pre-designed siRNA Set A contains three designed siRNAs for NRG3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

NRG4 Human Pre-designed siRNA Set A contains three designed siRNAs for NRG4 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

NRGN Human Pre-designed siRNA Set A contains three designed siRNAs for NRGN gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

NRIP1 Human Pre-designed siRNA Set A contains three designed siRNAs for NRIP1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

NRIP2 Human Pre-designed siRNA Set A contains three designed siRNAs for NRIP2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

NRIP3 Human Pre-designed siRNA Set A contains three designed siRNAs for NRIP3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

NRK Human Pre-designed siRNA Set A contains three designed siRNAs for NRK gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

NRL Human Pre-designed siRNA Set A contains three designed siRNAs for NRL gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

NRM Human Pre-designed siRNA Set A contains three designed siRNAs for NRM gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

NRN1 Human Pre-designed siRNA Set A contains three designed siRNAs for NRN1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

NRN1L Human Pre-designed siRNA Set A contains three designed siRNAs for NRN1L gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

NRP1 Human Pre-designed siRNA Set A contains three designed siRNAs for NRP1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

NRP2 Human Pre-designed siRNA Set A contains three designed siRNAs for NRP2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

NRPSs-IN-1 (Compound 7) is a cell-penetrating inhibitor of non-ribosomal peptide synthetase (NRPSs). NRPSs-IN-1 K inhibits gramicidin S synthetase A (GrsA) with a Kd value of 16.6 nM[1].

NRROS Human Pre-designed siRNA Set A contains three designed siRNAs for NRROS gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

NRTN Human Pre-designed siRNA Set A contains three designed siRNAs for NRTN gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

NRXN1 Human Pre-designed siRNA Set A contains three designed siRNAs for NRXN1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

NRXN2 Human Pre-designed siRNA Set A contains three designed siRNAs for NRXN2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

NRXN3 Human Pre-designed siRNA Set A contains three designed siRNAs for NRXN3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

NS2B/NS3-IN-8 (compound MH1) is a Zika virus NS2B-NS3 protease inhibitor[1].

NSA2 Human Pre-designed siRNA Set A contains three designed siRNAs for NSA2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

NSCLC-IN-1 (Compound A10-2) induces mitophagy and ferroptosis through targeting transmembrane BAX inhibitor motif containing 6 (TMBIM6). NSCLC-IN-1 induces mitochondrial Ca2+ imbalance, leading to mitochondrial damage. NSCLC-IN-1 reduces intracellular glutathione (GSH), increases the accumulation of lipid peroxides (LPO) and malondialdehyde (MDA) content. NSCLC-IN-1 is a potent anti-NSCLC agent[1].

NSD-IN-3 (compound 3) is a potent nuclear receptor binding SET domain (NSD) inhibitor. NSD-IN-3 inhibits NSD2-SET and NSD3-SET with IC50 values of 0.81 μM and 0.84 μM, respectively. NSD-IN-3 inhibits histone H3K36 dimethylation and decreases the expression of NSDs-targeted genes in non-small cell lung cancer cells. NSD-IN-3 induces s-phase cell cycle arrest and apoptosis[1].

NSD1 Human Pre-designed siRNA Set A contains three designed siRNAs for NSD1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

NSD2 Human Pre-designed siRNA Set A contains three designed siRNAs for NSD2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

NSD3 Human Pre-designed siRNA Set A contains three designed siRNAs for NSD3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

NSDHL Human Pre-designed siRNA Set A contains three designed siRNAs for NSDHL gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

NSF Human Pre-designed siRNA Set A contains three designed siRNAs for NSF gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

NSFL1C Human Pre-designed siRNA Set A contains three designed siRNAs for NSFL1C gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

NSG1 Human Pre-designed siRNA Set A contains three designed siRNAs for NSG1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

NSG2 Human Pre-designed siRNA Set A contains three designed siRNAs for NSG2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

NSL1 Human Pre-designed siRNA Set A contains three designed siRNAs for NSL1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

NSMAF Human Pre-designed siRNA Set A contains three designed siRNAs for NSMAF gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

NSMCE1 Human Pre-designed siRNA Set A contains three designed siRNAs for NSMCE1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

NSMCE2 Human Pre-designed siRNA Set A contains three designed siRNAs for NSMCE2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

NSMF Human Pre-designed siRNA Set A contains three designed siRNAs for NSMF gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Nsp12-IN-1is a nucleoside analogue. Nsp12-IN-1 can block the synthesis of viral RNA and inhibit viral replication. Nsp12-IN-1 can be used in the study of pan-coronavirus[1].

NSRP1 Human Pre-designed siRNA Set A contains three designed siRNAs for NSRP1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

NST-628 is a brain-permeable MAPK pathway molecule glue that inhibits RAF phosphorylation and MEK activation. NST-628 also binds RAF and prevents the formation of BRAF-CRAF and BRAF-ARAF heterodimers, effectively inhibiting the RAS-MAPK pathway. NST-628 inhibits RAS- and RAF-driven cancers and demonstrated potent inhibition in mutant KRAS, NRAS, BRAF class II/III, and NF1-mutant tumors[1].

NST-628 is a brain-permeable MAPK pathway molecule glue that inhibits RAF phosphorylation and MEK activation. NST-628 also binds RAF and prevents the formation of BRAF-CRAF and BRAF-ARAF heterodimers, effectively inhibiting the RAS-MAPK pathway. NST-628 inhibits RAS- and RAF-driven cancers and demonstrated potent inhibition in mutant KRAS, NRAS, BRAF class II/III, and NF1-mutant tumors[1].

NST-628 is a brain-permeable MAPK pathway molecule glue that inhibits RAF phosphorylation and MEK activation. NST-628 also binds RAF and prevents the formation of BRAF-CRAF and BRAF-ARAF heterodimers, effectively inhibiting the RAS-MAPK pathway. NST-628 inhibits RAS- and RAF-driven cancers and demonstrated potent inhibition in mutant KRAS, NRAS, BRAF class II/III, and NF1-mutant tumors[1].

NST-628 is a brain-permeable MAPK pathway molecule glue that inhibits RAF phosphorylation and MEK activation. NST-628 also binds RAF and prevents the formation of BRAF-CRAF and BRAF-ARAF heterodimers, effectively inhibiting the RAS-MAPK pathway. NST-628 inhibits RAS- and RAF-driven cancers and demonstrated potent inhibition in mutant KRAS, NRAS, BRAF class II/III, and NF1-mutant tumors[1].

NST-628 is a brain-permeable MAPK pathway molecule glue that inhibits RAF phosphorylation and MEK activation. NST-628 also binds RAF and prevents the formation of BRAF-CRAF and BRAF-ARAF heterodimers, effectively inhibiting the RAS-MAPK pathway. NST-628 inhibits RAS- and RAF-driven cancers and demonstrated potent inhibition in mutant KRAS, NRAS, BRAF class II/III, and NF1-mutant tumors[1].